First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress

Lung cancer is one of the most common cancers and the leading cause of cancer-related deaths worldwide. Most of these patients with non-small cell lung cancer (NSCLC) present with the advanced stage of the disease at the time of diagnosis, and thus decrease the 5-year survival rate to about 5%. Immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Zhangfeng, Su, Wenhao, Lu, Tong, Wang, Yuanyong, Dong, Yanting, Qin, Yi, Liu, Dahai, Sun, Lili, Jiao, Wenjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577011/
https://www.ncbi.nlm.nih.gov/pubmed/33117170
http://dx.doi.org/10.3389/fphar.2020.578091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577011/
https://www.ncbi.nlm.nih.gov/pubmed/33117170
http://dx.doi.org/10.3389/fphar.2020.578091

Ejemplares similares